- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/04 - AnorexiantsAntiobesity agents
Patent holdings for IPC class A61P 3/04
Total number of patents in this class: 7051
10-year publication summary
178
|
171
|
284
|
379
|
376
|
470
|
444
|
458
|
496
|
412
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Takeda Pharmaceutical Company Limited | 2705 |
84 |
Shionogi & Co., Ltd. | 849 |
71 |
Novo Nordisk A/S | 2287 |
69 |
Eli Lilly and Company | 3878 |
59 |
Pfizer Inc. | 3368 |
57 |
Boehringer Ingelheim International GmbH | 4642 |
56 |
Société des Produits Nestlé S.A. | 9312 |
47 |
Daiichi Sankyo Company, Limited | 1884 |
47 |
LG Chem, Ltd. | 17644 |
46 |
Janssen Pharmaceutica N.V. | 3369 |
45 |
Nestec S.A. | 2656 |
42 |
Taisho Pharmaceutical Co., Ltd. | 866 |
40 |
Novartis AG | 10730 |
38 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 833 |
37 |
The Regents of the University of California | 20059 |
36 |
Sunshine Lake Pharma Co., Ltd. | 599 |
36 |
Ajinomoto Co., Inc. | 2291 |
35 |
AstraZeneca AB | 2908 |
34 |
Bristol-myers Squibb Company | 4867 |
31 |
F. Hoffmann-La Roche AG | 7941 |
31 |
Other owners | 6110 |